Arvinas and Pfizer seek a new home for protein degrader drug

Arvinas and Pfizer, co-developers of vepdegestrant – the most advanced of the new bifunctional protein degrader drug class – are jointly seeking a new partner to bring it to market. The firms are looking to out-license the selective oestrogen receptor degrader (SERD) after clinical trial results published in March showed vepdgestrant works, but didn’t outperform existing treatments.